Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 26;26(13):6136.
doi: 10.3390/ijms26136136.

Kinetics of Phase Transitions in Amorphous Carbamazepine: From Sub- Tg Structural Relaxation to High-Temperature Decomposition

Affiliations

Kinetics of Phase Transitions in Amorphous Carbamazepine: From Sub- Tg Structural Relaxation to High-Temperature Decomposition

Roman Svoboda et al. Int J Mol Sci. .

Abstract

Thermokinetic characterization of amorphous carbamazepine was performed utilizing non-isothermal differential scanning calorimetry (DSC) and thermogravimetry (TGA). Structural relaxation of the amorphous matrix was described in terms of the Tool-Narayanaswamy-Moynihan model with the following parameters: Δh* ≈ 200-300 kJ·mol-1, β = 0.57, x = 0.44. The crystallization of the amorphous phase was modeled using complex Šesták-Berggren kinetics, which incorporates temperature-dependent activation energy and degree of autocatalysis. The activation energy of the crystal growth was determined to be >320 kJ·mol-1 at the glass transition temperature (Tg). Owing to such a high value, the amorphous carbamazepine is stable at Tg, allowing for extensive processing of the amorphous phase (e.g., self-healing of the quench-induced mechanical defects or internal stress). A discussion was conducted regarding the converse relation between the activation energies of relaxation and crystal growth, which is possibly responsible for the absence of sub-Tg crystal growth modes. The high-temperature thermal decomposition of carbamazepine proceeds via multistep kinetics, identically in both an inert and an oxidizing atmosphere. A complex reaction mechanism, consisting of a series of consecutive and competing reactions, was proposed to explain the second decomposition step, which exhibited a temporary mass increase. Whereas a negligible degree of carbamazepine degradation was predicted for the temperature characteristic of the pharmaceutical hot-melt extrusion (~150 °C), the degradation risk during the pharmaceutical 3D printing was calculated to be considerably higher (1-2% mass loss at temperatures 190-200 °C).

Keywords: carbamazepine; crystal growth; structural relaxation; thermal decomposition.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Raw DSC heating curves (right column); crystallization signals with subtracted thermokinetic background (left column). Exothermic effects evolve in an upward direction.
Figure 2
Figure 2
Temperature programs for the CR and CHR structural relaxation experiments (left column), and the corresponding DSC responses (right column). Exothermic effects evolve in an upward direction.
Figure 3
Figure 3
Selected joint DTA-TGA signals obtained for the CBZ decomposition in N2 and air atmospheres (left column)—exothermic effects evolve in a downward direction; the (right column) depicts full sets of TGA measurements.
Figure 4
Figure 4
The top left and right micrographs show the amorphous CBZ sample heated to 80 °C for 5 and 10 min, respectively. Bottom graphs show the Raman spectra (full and zoomed-in on the low-phonon part) of the amorphous, as-purchased, DSC crystalized, and surface-crystallized (crystals from the micrograph above) CBZ samples.
Figure 5
Figure 5
(Top graph): Evaluation of Δh* from CR and CHR cycles with the listed values corresponding to the linear fits (bottom and left axes); Δh*-T dependence determined from the CR cycles evaluation fit by the 2nd-order polynomial (top and right axes). (Middle graph): Normalized set of CHR cycles. (Bottom graph): Application of the simulation-comparative method to the present data—points show the experimental data from the middle graph, thin lines depict selected simulated dependences for various β&x combinations, thick red line shows the best correspondence between the experimental and simulated data (β = 0.57, x = 0.44).
Figure 6
Figure 6
(Top left graph): Kissinger evaluation of E using the temperatures corresponding to the crystallization peak onset and maximum with the listed values corresponding to the linear fits (bottom and left axes); E-T dependence determined from the Tp values fit by the 2nd-order polynomial (top and right axes). (Top right and middle graphs): q+ dependences of kinetic parameters determined by means of the sc-MKA method. (Bottom graphs): Example crystallization signal fit by either one or two AC processes.
Figure 7
Figure 7
(Top left graph): Kissinger evaluation of E using the temperatures corresponding to the TGA points of inflection determined from the derivative TGA data for the two step-like mass losses (bottom and left axes); E-T dependences determined from the Kissinger dependences fit by the 2nd-order polynomials (top and right axes). (Top right graph): Example TGA data (measured under N2 atmosphere) fit by the sc-MKA method employing the depicted reaction scheme. (Bottom graphs): Kinetic predictions calculated using the kinetic parameters determined for the 0.1 °C·min−1 TGA data-curve obtained under N2 atmosphere—the predictions were calculated for isothermal annealing at denoted temperatures characteristic for the processes of pharmaceutical hot melt extrusion and 3D printing.
Figure 8
Figure 8
(Top graph): Crystal growth rate data taken from [25] and transformed to evaluate the activation energy EG. (Bottom graph): Activation energies determined for various thermally induced processes occurring in (amorphous) CBZ. “Crystallization” and “crystal growth” denote the data from DSC and microscopy, respectively.
Scheme 1
Scheme 1
Molecular structure of carbamazepine.

Similar articles

References

    1. Yan R., Tuo J., Tai Z., Zhang H., Yang J., Yu C., Xu Z. Management of anti-seizure medications in lactating women with epilepsy. Front. Neurol. 2022;13:1005890. doi: 10.3389/fneur.2022.1005890. - DOI - PMC - PubMed
    1. Hakami T. Efficacy and tolerability of antiseizure drugs. Ther. Adv. Neurol. Disord. 2021;14:17562864211037430. doi: 10.1177/17562864211037430. - DOI - PMC - PubMed
    1. Cornett E.M., Amarasinghe S.N., Angelette A., Abubakar T., Kaye A.M., Kaye A.D., Neuchat E.E., Urits I., Viswanath O. Valtoco® (Diazepam nasal spray) for the acute treatment of intermittent stereotypic episodes of frequent seizure activity. Neurol. Int. 2021;13:64–78. doi: 10.3390/neurolint13010007. - DOI - PMC - PubMed
    1. Mirza N., Stevelink R., Taweel B., Koeleman B.P., Marson A.G. Using common genetic variants to find drugs for common epilepsies. Brain Commun. 2021;3:fcab287. doi: 10.1093/braincomms/fcab287. - DOI - PMC - PubMed
    1. Nierenberg A.A., Agustini B., Köhler-Forsberg O., Cusin C., Katz D., Sylvia L.G., Peters A., Berk M. Diagnosis and treatment of bipolar disorder: A review. JAMA. 2023;330:1370–1380. doi: 10.1001/jama.2023.18588. - DOI - PubMed

LinkOut - more resources